Workflow
调研速递|重药控股接受线上投资者等多家调研,聚焦市值管理与业务布局要点

Group 1 - The company held a half-year performance briefing on August 25, 2025, with key management personnel participating, including the chairman and general manager [1] - The company emphasized that market capitalization management is a key task for the year, having established a market value management system in June and approved a share buyback plan of 80 million to 100 million yuan at the end of July [1] - The company executed its first share buyback on August 14, repurchasing 3,762,300 shares for a total amount of 19,999,259 yuan (excluding transaction fees) [1] Group 2 - The company maintains a stable dividend policy, increasing the frequency and proportion of dividends to reward shareholders [1] - As of the end of June, the company has launched 199 SPD projects across 23 provinces in China and plans to develop new projects as needed [1] - The company operates 205 DTP pharmacies, with 192 directly operated and 13 franchised, and aims to significantly expand this business in the future [1] Group 3 - The acquirer plans to resolve competition issues with China National Pharmaceutical within five years through various measures such as asset restructuring [2] - The company is building a differentiated competitive system focused on "strengthening barriers, enhancing value, and exploring growth" while leveraging its state-owned enterprise background for synergy [2] - The company primarily invests in generic drug research and development, adhering to international standards, with four products approved and three in commercial production [2]